Pfizer (NYSE:PFE) Given Buy Rating at BMO Capital Markets

BMO Capital Markets reaffirmed their buy rating on shares of Pfizer (NYSE:PFE) in a research report sent to investors on Friday, November 10th. BMO Capital Markets currently has a $39.00 price objective on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on the company. Jefferies Group set a $35.00 target price on Pfizer and gave the company a neutral rating in a research note on Wednesday, August 2nd. Berenberg Bank set a $39.00 target price on Pfizer and gave the company a neutral rating in a research note on Tuesday, August 1st. Zacks Investment Research raised Pfizer from a hold rating to a buy rating and set a $40.00 price objective on the stock in a research note on Tuesday, October 3rd. Cowen set a $43.00 price objective on Pfizer and gave the stock a buy rating in a research note on Monday, August 14th. Finally, Vetr downgraded Pfizer from a buy rating to a hold rating and set a $35.71 price objective on the stock. in a research note on Wednesday, September 13th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $38.66.

Shares of Pfizer (PFE) traded up $0.36 during trading hours on Friday, reaching $36.21. The company’s stock had a trading volume of 15,279,399 shares, compared to its average volume of 19,998,613. The stock has a market capitalization of $213,690.00, a PE ratio of 14.20, a price-to-earnings-growth ratio of 2.51 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer has a fifty-two week low of $30.51 and a fifty-two week high of $36.78.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same period last year, the firm posted $0.61 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. equities analysts forecast that Pfizer will post 2.6 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.53%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio is presently 78.53%.

In other news, CEO Ian C. Read sold 197,168 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the sale, the chief executive officer now owns 580,318 shares in the company, valued at $19,730,812. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Frank A. Damelio sold 94,409 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $3,209,906.00. Following the completion of the sale, the executive vice president now owns 337,389 shares in the company, valued at approximately $11,471,226. The disclosure for this sale can be found here. Insiders sold 366,557 shares of company stock worth $12,532,406 over the last three months. Corporate insiders own 0.06% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer during the second quarter worth about $102,000. Mckinley Capital Management LLC Delaware acquired a new position in Pfizer during the 2nd quarter worth approximately $103,000. D. Scott Neal Inc. boosted its stake in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares in the last quarter. Herndon Capital Management LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $120,000. Finally, Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of Pfizer during the 1st quarter worth approximately $121,000. Institutional investors and hedge funds own 69.90% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally posted by BBNS and is owned by of BBNS. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://baseballnewssource.com/markets/pfizer-inc-pfe-rating-reiterated-by-bmo-capital-markets/1775116.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.